Literature DB >> 22933621

Prolactin in multiple sclerosis.

Simon Zhornitsky1, V Wee Yong, Samuel Weiss, Luanne M Metz.   

Abstract

Multiple sclerosis (MS) is more common among women than men. MS often goes into remission during pregnancy, when prolactin (PRL) levels are known to be high. In an animal model of demyelination, PRL promoted myelin repair, suggesting it has potential as a remyelinating therapy in MS. In this systematic review, we examined the known associations between PRL and MS, in order to elucidate its potential role in the pathophysiology and treatment of MS. A systematic search was performed in the electronic databases PubMed and EMBASE, using the keywords "prolactin" AND "multiple sclerosis." The inclusion criteria were met by 23 studies. These studies suggested to us that elevated PRL may be more common in MS patients than in controls. Hyperprolactinemia may also be associated with clinical relapse in MS, especially among patients with hypothalamic lesions or optic neuritis; however, it is unknown if this is a cause or consequence of a relapse. Overall, most people with MS have normal PRL levels. The impact of PRL on MS outcomes remains unclear.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22933621     DOI: 10.1177/1352458512458555

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  14 in total

Review 1.  Disease-Modifying Treatment in Progressive Multiple Sclerosis.

Authors:  John Robert Ciotti; Anne Haney Cross
Journal:  Curr Treat Options Neurol       Date:  2018-04-07       Impact factor: 3.598

2.  Prolactin is Not Associated with Disability and Clinical Forms in Patients with Multiple Sclerosis.

Authors:  Wildéa Lice de Carvalho Jennings Pereira; Tamires Flauzino; Daniela Frizon Alfieri; Sayonara Rangel Oliveira; Ana Paula Kallaur; Andrea Name Colado Simão; Marcell Alysson Batisti Lozovoy; Damacio Ramón Kaimen-Maciel; Michael Maes; Edna Maria Vissoci Reiche
Journal:  Neuromolecular Med       Date:  2019-08-31       Impact factor: 3.843

Review 3.  Therapeutic Advances and Future Prospects in Progressive Forms of Multiple Sclerosis.

Authors:  Afsaneh Shirani; Darin T Okuda; Olaf Stüve
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

4.  Prolactin promotes cartilage survival and attenuates inflammation in inflammatory arthritis.

Authors:  Norma Adán; Jessica Guzmán-Morales; Maria G Ledesma-Colunga; Sonia I Perales-Canales; Andrés Quintanar-Stéphano; Fernando López-Barrera; Isabel Méndez; Bibiana Moreno-Carranza; Jakob Triebel; Nadine Binart; Gonzalo Martínez de la Escalera; Stéphanie Thebault; Carmen Clapp
Journal:  J Clin Invest       Date:  2013-08-01       Impact factor: 14.808

Review 5.  Breaking the barriers to remyelination in multiple sclerosis.

Authors:  Marjan Gharagozloo; Riley Bannon; Peter A Calabresi
Journal:  Curr Opin Pharmacol       Date:  2022-03-04       Impact factor: 5.547

Review 6.  Newly Identified Deficiencies in the Multiple Sclerosis Central Nervous System and Their Impact on the Remyelination Failure.

Authors:  Giuseppe Scalabrino
Journal:  Biomedicines       Date:  2022-03-30

7.  Prevalence of autoimmune disease in patients with prolactinomas and non-functioning pituitary adenomas.

Authors:  V Larouche; J A Correa; P Cassidy; C Beauregard; N Garfield; J Rivera
Journal:  Pituitary       Date:  2016-04       Impact factor: 4.107

Review 8.  Impact of sex hormones on immune function and multiple sclerosis development.

Authors:  María C Ysrraelit; Jorge Correale
Journal:  Immunology       Date:  2018-10-11       Impact factor: 7.397

9.  Prolactin in combination with interferon-β reduces disease severity in an animal model of multiple sclerosis.

Authors:  Simon Zhornitsky; Trina A Johnson; Luanne M Metz; Samuel Weiss; V Wee Yong
Journal:  J Neuroinflammation       Date:  2015-03-19       Impact factor: 8.322

10.  Relationship between Prolactin Plasma Levels and White Matter Volume in Women with Multiple Sclerosis.

Authors:  L De Giglio; F Marinelli; L Prosperini; G M Contessa; F Gurreri; M C Piattella; F De Angelis; V T Barletta; V Tomassini; P Pantano; C Pozzilli
Journal:  Mediators Inflamm       Date:  2015-07-08       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.